A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Imagem de Miniatura
Arquivos
art_MISSIO_A_randomized_controlled_trial_comparing_lithium_plus_valproic_2019.PDF (956.43 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
BARROS, Vivian Boschesi
Citação
TRIALS, v.20, n.1, article ID 608, 9p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Treatment of bipolar disorder (BD) usually requires drug combinations. Combinations of lithium plus valproic acid (Li/VPA) and lithium plus carbamazepine (Li/CBZ) are used in clinical practice but were not previously compared in a head-to-head trial. Objective The objective of this trial was to compare the efficacy and tolerability of Li/VPA versus Li/CBZ in treating type 1 BD in any phase of illness in young individuals. Methods LICAVAL was a randomized, unicenter, open-label, parallel-group trial that was conducted from January 2009 to December 2012 in a tertiary hospital in Sao Paulo, Brazil. Participants were between 18 and 35 years old and were followed up for 2 years. Our primary outcome was the number of participants achieving/maintaining response and remission during the acute and maintenance phases of BD treatment, respectively. Other outcomes assessed were symptom severity and adverse events throughout the study. In the analysis of the primary outcome, we compared groups by using a two-way repeated measures analysis of variance and estimated effect sizes by using Cohen's d. Results Of our 64 participants, 36 were allocated to Li/VPA and 28 to Li/CBZ. Our sample was composed predominantly of females (66.6%) and the average age was 27.8 years. A total of 27 (45.0%) participants had depression, 17 (28.3%) had mania/hypomania, and 16 (26.7%) had a mixed state. We found no between-group differences in CGI-BP (Clinical Global Impression Scale modified for use in bipolar disorder) scores (P = 0.326) or in any other outcome. Side effects differed significantly between groups only in the first week of treatment (P = 0.021), and there were more side effects in the Li/VPA group. Also, the Li/VPA group gained weight (+2.1 kg) whereas the Li/CBZ group presented slight weight loss (-0.2 kg). Conclusion Our study suggests that Li/VPA and Li/CBZ have similar efficacy and tolerability in BD but that Li/CBZ might have metabolic advantages in the long term.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/34729
Referências
  1. Andrews G, 1999, AUST NZ J PSYCHIAT, V33, P316, DOI 10.1046/j.1440-1614.1999.00581.x
  2. Baethge C, 2005, J CLIN PSYCHIAT, V66, P174, DOI 10.4088/JCP.v66n0204
  3. Berk M, 2009, INT J NEUROPSYCHOPH, V12, P441, DOI 10.1017/S1461145708009498
  4. Bocchetta A, 1997, J CLIN PSYCHOPHARM, V17, P92, DOI 10.1097/00004714-199704000-00005
  5. Caetano D, 1993, J BRAS PSIQUIAT, V42, P255
  6. CALABRESE JR, 1990, AM J PSYCHIAT, V147, P431
  7. Conley, 2000, J CLIN PSYCHIAT, V61, P12
  8. Denicoff KD, 1997, J CLIN PSYCHIAT, V58, P470, DOI 10.4088/JCP.v58n1102
  9. DICOSTANZO E, 1991, ACTA PSYCHIAT SCAND, V83, P456
  10. First MB, 2013, STRUCTURED CLIN INTE
  11. Fornaro M, 2016, NEUROPSYCH DIS TREAT, V12, P719, DOI 10.2147/NDT.S100846
  12. Freeman MP, 1998, AM J PSYCHIAT, V155, P12, DOI 10.1176/ajp.155.1.12
  13. Geddes John R, 2002, World Psychiatry, V1, P48
  14. Goodwin FK, 2003, J CLIN PSYCHIAT, V64, P18
  15. Governo do Estado de SAo Paulo, 2018, REL EST MED COMP ESP
  16. Grande I, 2013, INT J NEUROPSYCHOPH, V16, P513, DOI 10.1017/S1461145712000405
  17. Granneman GR, 1996, J CLIN PSYCHIAT, V57, P204
  18. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  19. Johnson FR, 2007, MED CARE, V45, P545, DOI 10.1097/MLR.0b013e318040ad90
  20. Keck PE, 2003, J CLIN PSYCHIAT, V64, P1426, DOI 10.4088/JCP.v64n1205
  21. Keck PE, 2002, J CLIN PSYCHIAT, V63, P13
  22. KISHIMOTO A, 1992, PROG NEURO-PSYCHOPH, V16, P483
  23. KRAMLINGER KG, 1989, ACTA PSYCHIAT SCAND, V79, P378, DOI 10.1111/j.1600-0447.1989.tb10273.x
  24. Ministerio da Saude brasileiro, 2017, RELACAO NACL MEDICAM
  25. Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
  26. Muller-Oerlinghausen B, 1999, CNS DRUGS, V11, P41
  27. Domecq JP, 2015, J CLIN ENDOCR METAB, V100, P363, DOI 10.1210/jc.2014-3421
  28. Reischies FM, 2002, NEUROPSYCHOBIOLOGY, V46, P22, DOI 10.1159/000068020
  29. SHARMA V, 1993, CAN J PSYCHIAT, V38, P137, DOI 10.1177/070674379303800213
  30. SHUKLA S, 1985, J AFFECT DISORDERS, V9, P219, DOI 10.1016/0165-0327(85)90051-5
  31. Spearing MK, 1997, PSYCHIAT RES, V73, P159, DOI 10.1016/S0165-1781(97)00123-6
  32. Sturma D, 2009, JB WISSENSCHAFT ETHI, V14, DOI [10. 1515/9783110208856. 233, DOI 10.1515/9783110208856.233]
  33. Vilela JAA, 2005, BRAZ J MED BIOL RES, V38, P1429, DOI 10.1590/S0100-879X2005000900019
  34. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23